Eytan Rosenbloom
Interventional Pain Medicine · Englewood Cliffs, NJNPI 1922595842
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,037 of the $3,261 with a category attached, or 62.5%. Abbott accounts for 85.1% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $3,060 and has fallen 97.2% since, to $85 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in NJ, where the typical reported total is $3,760.
Across 25 payments — averaging $130.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Nevro Corp.$140
- Curonix LLC$127
- Medtronic$115
- SPR Therapeutics, Inc$53
- Johnson & Johnson$32
- plus $18 from 1 others
What the payments were for
- Travel & lodging$2,03762%
- Food & beverage$1,22438%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 14 | $2,775 |
| Nevro Corp. | 3 | $140 |
| Curonix LLC | 1 | $127 |
| Medtronic | 2 | $115 |
| SPR Therapeutics, Inc | 3 | $53 |
| Johnson & Johnson | 1 | $32 |
| Bioventus LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,261 in reported general payments places this provider in the 40th percentile of 82 interventional pain medicine providers in New Jersey.
See all interventional pain medicine providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 266 | $1,436 |
| Tizanidine Hcl | 74 | $332 |
| Cyclobenzaprine Hcl | 40 | $300 |
| Methylprednisolone | 40 | $273 |
| Pregabalin | 22 | $205 |
| Naproxen | 31 | $189 |
| Meloxicam | 45 | $143 |
| Diclofenac Sodium | 16 | $135 |
| Baclofen | 17 | $131 |
| Celecoxib | 12 | $115 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Englewood Cliffs
- Youssef JosephsonWest Deptford$496K
- Ali ValimahomedHolmdel$415K
- Saurabh DangEdgewater$157K
- Gabriele JasperBrick$114K
- Matthew LippChatham$67K
- Didier DemesminSomerset$33K
- Steve AydinFranklin Lakes$22K
- Kieran SlevinHainesport$21K
- John CoccaroToms River$17K
- Dinash YanamadulaLawrenceville$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.